A new clinical trial is due to begin which will test experimental hematopoietic stem cell treatment (HSCT) against biological therapy for relapsing remitting multiple sclerosis (RRMS). Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in the US, the study will compare the safety, efficacy and cost-effectiveness of the two treatments.
BEAT-MS will enrol 156 people between the ages of 18 to 55 in both the US and the UK on the trial, and compare autologous hematopoietic stem cell transplant (AHSCT) – a type of bone marrow transplantation – to the most effective medicines regularly used to treat RRMS. Participants will be randomly assigned a treatment, so will not be able to choose which one they receive. They will then be followed by a neurologist from the study for six years.
There is detailed eligibility criteria for the study, but firstly you must have been diagnosed with RRMS, and had continued relapses or an active magnetic resonance imaging (MRI) while taking your prescription medication for MS within the last two years.
To find out more and discover if you are eligible, visit www.beat-ms.org